Bethesda and Gaithersburg, MD - December 10, 2007 - Micromet, Inc. (Nasdaq: MITI) and MedImmune, Inc. yesterday presented new data from an ongoing Phase 1 clinical trial showing potent single-agent activity of MT103 in patients with late-stage non-Hodgkin's lymphoma (NHL). MT103, also known as MEDI-538, is a recombinant T-cell engaging antibody, or BiTE® antibody targeting the CD19 antigen, ...
Full story here
